SCHEMBL5753718

SCHEMBL5753718

CC(C)C(O)(c1ccc2cc(NS(C)(=O)=O)ccc2c1)c1cn(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.38
CYP17A1 P05093 2/20 0.37
SIRT2 Q8IXJ6 3/20 0.35
CYP3A4 P08684 2/20 0.34
KMT2A Q03164 1/20 0.34
PTGS2 P35354 1/20 0.34
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPY2R P49146 1/20 0.33
MET P08581 1/20 0.33
KCNH2 Q12809 1/20 0.33
RORC P51449 1/20 0.33
PHGDH O43175 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HPGD P15428 1/20 0.33
BRPF1 P55201 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030863 0.87 CYP17A1 (0.52) CYP17A1SIRT2CYP3A4KMT2A
SCHEMBL5748871 0.85 CYP17A1 (0.53) CYP17A1SIRT2CYP3A4SMN1; SMN2
SCHEMBL5754336 0.84 CYP17A1 (0.41) CYP17A1SIRT2CYP3A4
SCHEMBL5753019 0.82 CYP3A4 (0.39) CYP17A1SIRT2CYP3A4RORC
SCHEMBL1414974 0.82 CYP3A4 (0.39) CYP17A1SIRT2CYP3A4RORC
SCHEMBL5750054 0.81 CYP3A4 (0.49) CYP17A1SIRT2CYP3A4HPGD
SCHEMBL4026360 0.81 CYP3A4 (0.42) CYP17A1SIRT2CYP3A4
SCHEMBL1414885 0.81 CYP17A1 (0.41) CYP17A1SIRT2CYP3A4
SCHEMBL5682244 0.81 CYP3A4 (0.38) CYP17A1SIRT2CYP3A4RORC
SCHEMBL4028694 0.81 CYP3A4 (0.38) CYP17A1SIRT2CYP3A4RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084149-B2 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-08-01 US disclosed
EP-1073640-B1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL (JP) 2005-04-13 EP disclosed
US-20030236274-A1 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-25 US disclosed
US-6573289-B1 Naphthalene derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-06-03 US disclosed
EP-1073640-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2001-02-07 EP disclosed
WO-1999054309-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236274-A1 Naphthalene derivatives, their production and use CYP17A1, CYP21A2, HSD17B1 NR3C2 38/4885CYP17A1 1/4885SIRT2 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.